Do we need more than one antidepressant for patients with major depressive disorder?

Chi Un Pae, Changsu Han, Tae Youn Jun

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Evaluation of: Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168(7), 689-701 (2011). According to currently existing treatment guidelines, when a single antidepressant medication is not working, the common next step treatment is to switch to another class of antidepressants or to add another one to the first therapeutic agent. With regard to this issue, combination therapy has been suggested to provide unexpected synergy for patients, resulting in more remission compared with switching strategies, although some debates are still ongoing. Recently, Rush and colleagues have investigated whether two antidepressant combination treatments should produce a higher remission rate in first-step acute-phase (12 weeks) and long-term (7 months) treatment compared with monotherpay. They failed to find any superiority of combination treatment over monotherapy in terms of efficacy and safety. The remission and response rates and most secondary outcomes were not different among treatment groups at 12 weeks and 7 months, while the mean number of worsening adverse events was higher for combination treatment (5.7) than for monotherapy (4.7) at 12 weeks. This article will discuss the clinical and further research implications in the context of the potential limitations and significance of this recent study.

Original languageEnglish
Pages (from-to)1561-1564
Number of pages4
JournalExpert Review of Neurotherapeutics
Volume11
Issue number11
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Major Depressive Disorder
Antidepressive Agents
Therapeutics
Single-Blind Method
Psychiatry
Guidelines
Depression
Safety

Keywords

  • antidepressant
  • combination
  • evidence
  • guideline
  • major depressive disorder
  • monotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Do we need more than one antidepressant for patients with major depressive disorder? / Pae, Chi Un; Han, Changsu; Jun, Tae Youn.

In: Expert Review of Neurotherapeutics, Vol. 11, No. 11, 01.11.2011, p. 1561-1564.

Research output: Contribution to journalArticle

@article{3d80973d094d44f08074741afa8fee29,
title = "Do we need more than one antidepressant for patients with major depressive disorder?",
abstract = "Evaluation of: Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168(7), 689-701 (2011). According to currently existing treatment guidelines, when a single antidepressant medication is not working, the common next step treatment is to switch to another class of antidepressants or to add another one to the first therapeutic agent. With regard to this issue, combination therapy has been suggested to provide unexpected synergy for patients, resulting in more remission compared with switching strategies, although some debates are still ongoing. Recently, Rush and colleagues have investigated whether two antidepressant combination treatments should produce a higher remission rate in first-step acute-phase (12 weeks) and long-term (7 months) treatment compared with monotherpay. They failed to find any superiority of combination treatment over monotherapy in terms of efficacy and safety. The remission and response rates and most secondary outcomes were not different among treatment groups at 12 weeks and 7 months, while the mean number of worsening adverse events was higher for combination treatment (5.7) than for monotherapy (4.7) at 12 weeks. This article will discuss the clinical and further research implications in the context of the potential limitations and significance of this recent study.",
keywords = "antidepressant, combination, evidence, guideline, major depressive disorder, monotherapy",
author = "Pae, {Chi Un} and Changsu Han and Jun, {Tae Youn}",
year = "2011",
month = "11",
day = "1",
doi = "10.1586/ern.11.150",
language = "English",
volume = "11",
pages = "1561--1564",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Do we need more than one antidepressant for patients with major depressive disorder?

AU - Pae, Chi Un

AU - Han, Changsu

AU - Jun, Tae Youn

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Evaluation of: Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168(7), 689-701 (2011). According to currently existing treatment guidelines, when a single antidepressant medication is not working, the common next step treatment is to switch to another class of antidepressants or to add another one to the first therapeutic agent. With regard to this issue, combination therapy has been suggested to provide unexpected synergy for patients, resulting in more remission compared with switching strategies, although some debates are still ongoing. Recently, Rush and colleagues have investigated whether two antidepressant combination treatments should produce a higher remission rate in first-step acute-phase (12 weeks) and long-term (7 months) treatment compared with monotherpay. They failed to find any superiority of combination treatment over monotherapy in terms of efficacy and safety. The remission and response rates and most secondary outcomes were not different among treatment groups at 12 weeks and 7 months, while the mean number of worsening adverse events was higher for combination treatment (5.7) than for monotherapy (4.7) at 12 weeks. This article will discuss the clinical and further research implications in the context of the potential limitations and significance of this recent study.

AB - Evaluation of: Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168(7), 689-701 (2011). According to currently existing treatment guidelines, when a single antidepressant medication is not working, the common next step treatment is to switch to another class of antidepressants or to add another one to the first therapeutic agent. With regard to this issue, combination therapy has been suggested to provide unexpected synergy for patients, resulting in more remission compared with switching strategies, although some debates are still ongoing. Recently, Rush and colleagues have investigated whether two antidepressant combination treatments should produce a higher remission rate in first-step acute-phase (12 weeks) and long-term (7 months) treatment compared with monotherpay. They failed to find any superiority of combination treatment over monotherapy in terms of efficacy and safety. The remission and response rates and most secondary outcomes were not different among treatment groups at 12 weeks and 7 months, while the mean number of worsening adverse events was higher for combination treatment (5.7) than for monotherapy (4.7) at 12 weeks. This article will discuss the clinical and further research implications in the context of the potential limitations and significance of this recent study.

KW - antidepressant

KW - combination

KW - evidence

KW - guideline

KW - major depressive disorder

KW - monotherapy

UR - http://www.scopus.com/inward/record.url?scp=80054938952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054938952&partnerID=8YFLogxK

U2 - 10.1586/ern.11.150

DO - 10.1586/ern.11.150

M3 - Article

C2 - 22014134

AN - SCOPUS:80054938952

VL - 11

SP - 1561

EP - 1564

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 11

ER -